ID   RT112/D21
AC   CVCL_6215
SY   RT-112-D21
DR   cancercelllines; CVCL_6215
DR   CLS; 300325
DR   Wikidata; Q54951357
RX   PubMed=7740654;
RX   PubMed=29732388;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): CLS
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13,14
ST   D16S539: 11,13
ST   D18S51: 15
ST   D21S11: 27,30
ST   D3S1358: 15
ST   D5S818: 10,13
ST   D7S820: 11,12
ST   D8S1179: 13,15
ST   FGA: 23
ST   Penta D: 10,11
ST   Penta E: 12,16
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1670 ! RT-112
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=7740654; DOI=10.1007/BF00296874;
RA   Seemann O., Muscheck M., Siegsmund M.J., Pilch H., Nebe C.T.,
RA   Rassweiler J., Alken P.;
RT   "Establishment and characterization of a multidrug-resistant human
RT   bladder carcinoma cell line RT112/D21.";
RL   Urol. Res. 22:353-360(1995).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//